Nasdaq Grants Sesen Bio Exception From Listing Non-Compliance To Complete Proposed Merger With Carisma Therapeutics
On February 24, 2023, Sesen Bio, Inc. (the “Company”) received a determination from The Nasdaq Stock Market LLC (“Nasdaq”) Office of General Counsel that the Nasdaq Hearings Panel (the